Clinical Trial Information
Call 800-811-8480

For Healthcare Professionals

Clinical Trial COGAALL07P1

Title

A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Principal Investigator(s)

Haydar Frangoul

Details

  • Protocol No. COGAALL07P1
  • Open Date: 01/26/2011
  • Staging: Phase II
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To estimate the toxicity, CR2 rate at end of Block 1 therapy, and 4-month EFS for pediatric and young adult patients with relapsed ALL treated with bortezomib in combination with intensive Re-Induction chemotherapy.
  • Disease Sites: Leukemia; Lymphoma; Pediatric Leukemia; Pediatric Lymphoma
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics; Therapy (NOS)
  • Drugs: Bortezomib (BTZ); Cyclophosphamide (CTX); Cytarabine (ARA-C); Doxorubicin; Etoposide; L-Asparaginase; Methotrexate; Pegaspargase (Oncaspar); Prednisone; VELCADE; Vincristine
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: AALL07P1

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.